Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:04:35 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:AMRN - AMARIN CORP ADR EACH REP 1 ORD GBP0.50 - http://www.amarincorp.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AMRN - Q0.20.8752·0.8810.20.8809+0.0060.7274.72074120.854  0.882  0.8541.485  0.65111:47:28Apr 2415 min RT 2¢

Recent Trades - Last 10 of 412
Time ETExPriceChangeVolume
11:47:28Q0.88090.0064,000
11:44:36Q0.87810.003292
11:44:36Q0.87810.00321
11:42:36Q0.87520.00032,305
11:41:42Q0.88170.00681,255
11:41:42Q0.88170.00683,745
11:39:38Q0.88170.006827
11:38:10Q0.88170.0068500
11:37:54Q0.87850.0036100
11:37:54Q0.88170.0068100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-24 14:00U:AMRNNews ReleaseAmarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
2024-04-22 08:00U:AMRNNews ReleaseAmarin Announces Results of Annual General Meeting of Shareholders
2024-04-15 08:00U:AMRNNews ReleaseAmarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
2024-04-08 08:00U:AMRNNews ReleaseAmarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
2024-04-08 06:30U:AMRNNews ReleaseNew REDUCE-IT(TM) Analyses Show VASCEPA(TM) (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
2024-04-06 15:30U:AMRNNews ReleaseNew REDUCE-IT(TM) Analyses Show VASCEPA(TM)/VAZKEPA(TM) (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
2024-04-03 08:00U:AMRNNews ReleaseAmarin Provides Update on VAZKEPA(TM) (Icosapent Ethyl) Intellectual Property Portfolio in Europe
2024-03-25 08:00U:AMRNNews ReleaseResearch Evaluating Benefits of VASCEPA(TM)/VAZKEPA(TM) (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo
2024-02-29 07:00U:AMRNNews ReleaseAmarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-02-15 08:00U:AMRNNews ReleaseAmarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
2024-01-22 07:30U:AMRNNews ReleaseAmarin Chairman & CEO Issue Letter to Shareholders
2024-01-10 07:00U:AMRNNews ReleaseAmarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
2023-12-11 08:00U:AMRNNews ReleaseAmarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-12 09:00U:AMRNNews ReleaseNew REDUCE-IT ‚ ® Analyses Show VASCEPA ‚ ® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
2023-11-01 07:00U:AMRNNews ReleaseAmarin Reports Third Quarter 2023 Financial Results
2023-10-31 12:00U:AMRNNews ReleaseAmarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
2023-10-26 08:00U:AMRNNews ReleaseLatest Research Evaluating VASCEPA ‚ ®/VAZKEPA ‚ ® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023
2023-10-19 08:00U:AMRNNews Release ‚  Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
2023-09-12 08:00U:AMRNNews ReleaseAmarin to Present at the 2023 Cantor Global Healthcare Conference
2023-08-09 16:05U:AMRNNews ReleaseAmarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy